StockData

Lensar vs Profound Medical

LNSR and PROF side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LNSR and PROF compare

Profound Medical grew revenue faster over the last twelve months (65.3% versus 1.6% for Lensar).

Lensar keeps more of each dollar of sales as profit, with a net margin of 56.1% compared with −138% at Profound Medical.

Lensar scores higher on the StockData Score (8 against 5 for Profound Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLNSRPROF
Size and price
Market cap$56.3M–
Share price$4.58$7.85
Change, 1 year−55.0%31.1%
Change, 5 years−35.5%−35.6%
Beta (5Y)0.581.03
Employees150162
StockData Score
Total score8 (better)5
Valuation score2 (better)0
Growth score23 (better)
Performance score2 (better)0
Health score22
Dividend score00
Valuation
P/S0.9×–
P/B5.1×–
Fair value$6.18–
Margin of safety25.9%–
Growth
Revenue growth (TTM)1.6%65.3% (better)
Revenue growth, 5Y average17.2% (better)17.1%
EPS growth, 5Y average–2.4%
Profitability
Gross margin52.0%73.9% (better)
Operating margin−3.3% (better)−145%
Net margin56.1% (better)−138%
Return on equity–−87.0%
Return on invested capital–−213%
Financial health
Debt / equity0.170.11 (better)
Interest coverage–−105.8×
Current ratio2.254.54 (better)
Altman Z-score−0.93–
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions36.0%45.2%
Held by insiders–1.6%
Short interest, % of float–4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.